Correspondence between the CYP2C19 and CYP3A4 genotypes with the inferred metabolizer phenotype by omeprazole administration in Mexican healthy children

Favela-Mendoza, Alma Faviola; Martínez-Cortés, Gabriela; Romero-Prado, Marina María de Jesús; Romero-Tejeda, Elba M.; Islas-Carbajal, María Cristina; Sosa-Macías, Martha; Lares‐Asseff, Ismael; Rangel-Villalobos, Héctor

doi:10.1111/jcpt.12699

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The probability of having a CYP2C19 non-NM predicted phenotype due to high frequencies of the non-functional CYP2C19*2 allele and/or the increased function CYP2C19 * 17 allele is highest in India (non-NM probability estimate 80.1%) 56 , 60 , 61 , Pakistan (non-NM probability estimate 74.8%) 55 , 62 , 63 , and Iran (non-NM probability estimate 69.2%) 64 , 65 . The probability is lowest in countries in the Americas, particularly Mexico (non-NM probability estimate 31.7%) 66 – 68 and Costa Rica (non-NM probability estimate 33.9%) 69 . CYP2C19 non-NM probability estimates are shown in Fig.…”

Section: Resultsmentioning

confidence: 98%

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19

et al. 2021

View full text Add to dashboard Cite

Extensive migration has led to the necessity of knowledge regarding the treatment of migrants with different ethnical backgrounds. This is especially relevant for pharmacological treatment, because of the significant variation between migrant groups in their capacity to metabolize drugs. For psychiatric medications, CYP2D6 and CYP2C19 enzymes are clinically relevant. The aim of this meta-analysis was to analyze studies reporting clinically useful information regarding CYP2D6 and CYP2C19 genotype frequencies, across populations and ethnic groups worldwide. To that end, we conducted a comprehensive meta-analysis using Embase, PubMed, Web of Science, and PsycINFO (>336,000 subjects, 318 reports). A non-normal metabolizer (non-NM) probability estimate was introduced as the equivalent of the sum-prevalence of predicted poor, intermediate, and ultrarapid metabolizer CYP2D6 and CYP2C19 phenotypes. The probability of having a CYP2D6 non-NM predicted phenotype was highest in Algeria (61%) and lowest in Gambia (2.7%) while the probability for CYP2C19 was highest in India (80%) and lowest in countries in the Americas, particularly Mexico (32%). The mean total probability estimates of having a non-NM predicted phenotype worldwide were 36.4% and 61.9% for CYP2D6 and CYP2C19, respectively. We provide detailed tables and world maps summarizing clinically relevant data regarding the prevalence of CYP2D6 and CYP2C19 predicted phenotypes and demonstrating large inter-ethnic differences. Based on the documented probability estimates, pre-emptive pharmacogenetic testing is encouraged for every patient who will undergo therapy with a drug(s) that is metabolized by CYP2D6 and/or CYP2C19 pathways and should be considered in case of treatment resistance or serious side effects.

show abstract

Section: Resultsmentioning

confidence: 98%

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Importantly, CYP3A4 exhibits significant genetic polymorphisms, which affect the metabolic characteristics of clinical drugs (Zhou and Lauschke, 2022). Studies on this include the association of CYP3A4*1B with tacrolimus (Luo et al, 2016), midazolam (He et al, 2005), and omeprazole (Favela-Mendoza et al, 2018). The association between CYP3A4*20 and the pharmacokinetics profile of irinotecan was also reported (Riera et al, This article has not been copyedited and formatted.…”

Section: Introductionmentioning

confidence: 99%

Gene Polymorphisms and Drug–Drug Interactions Determine the Metabolic Profile of Blonanserin

Ye,

Li,

et al. 2023

J Pharmacol Exp Ther

View full text Add to dashboard Cite

This study aimed to evaluate the effects of cytochrome P450 3A4 (CYP3A4) gene polymorphism and drug interaction on the metabolism of blonanserin. Human recombinant CYP3A4 was prepared using the Bac-to-Bac baculovirus expression system. A microsomal enzyme reaction system was established, and drug-drug interactions were evaluated using Sprague-Dawley rats.Ultra-performance liquid chromatography-tandem mass spectrometry was used to detect the concentrations of blonanserin and its metabolite. Compared with wild-type CYP34A, the relative clearance of blonanserin by CYP3A4.29 significantly increased to 251.3%, while it decreased

show abstract

Toward precision medicine in pediatric population using cytochrome P450 phenotyping approaches and physiologically based pharmacokinetic modeling

et al. 2019

View full text Add to dashboard Cite

Correspondence between the CYP2C19 and CYP3A4 genotypes with the inferred metabolizer phenotype by omeprazole administration in Mexican healthy children

Abstract: The CYP2C19 phenotype is not predicted by the number of functional alleles of CYP2C19 and CYP3A4 genes. Phenotyping is still the most valuable alternative to dose individualization for CYP2C19 substrate drugs.

Cited by 3 publications

References 21 publications

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19

Gene Polymorphisms and Drug–Drug Interactions Determine the Metabolic Profile of Blonanserin

Toward precision medicine in pediatric population using cytochrome P450 phenotyping approaches and physiologically based pharmacokinetic modeling

Contact Info

Product

Resources

About